Clinical usefulness of longitudinal IL-6 monitoring in a patient with Takayasu aortitis receiving tocilizumab.

[1]  M. Recher,et al.  Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses , 2019, Annals of the rheumatic diseases.

[2]  J. Gottenberg,et al.  Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. , 2018, Journal of autoimmunity.

[3]  P. Zhu,et al.  An increased major vessel uptake by 18F-FDG-PET/CT in NIH criteria inactive patients with Takayasu's arteritis. , 2018, Clinical and experimental rheumatology.

[4]  Hong-chen Shi,et al.  18F-FDG-PET/CT: an accurate method to assess the activity of Takayasu’s arteritis , 2018, Clinical Rheumatology.

[5]  M. Isobe,et al.  Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study) , 2017, Annals of the rheumatic diseases.

[6]  C. Kallenberg,et al.  Are cytokines and chemokines suitable biomarkers for Takayasu arteritis? , 2017, Autoimmunity reviews.

[7]  L. Magnani,et al.  Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. , 2017, Clinical and experimental rheumatology.

[8]  K. Kasai,et al.  Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. , 2012, Cytokine.